CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN (CAP) IN THE TREATMENT OF UROTHELIAL MALIGNANCY - A PILOT-STUDY OF THE SOUTHEASTERN-CANCER-STUDY-GROUP

  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (1-2) , 29-32
Abstract
Thirty-four patients with urothelial malignancy were treated with a chemotherapy regimen of cyclophosphamide, doxorubicin and cisplatin. The objective response rate was 38% (13 of 34 patients), with 3 patients achieving a complete remission. Objective responders had a significantly longer median survival time than nonresponders (225 vs. 137 days [P .ltoreq. 0.04]). The median duration of remission was 177 days. Hematologic toxic effects were initially severe, with 3 episodes of sepsis and 1 death, but were acceptable after dose modification. The regimen of cyclophosphamide, doxorubicin and cisplatin apparently is effective in metastatic urothelial malignancy. Although response duration was short (25 wk), responders clearly lived longer than nonresponders.